Brought to you by 
Metamark Genetics brings in $22mm through start of Series B; later adds $13mm
06 Nov 2012
Executive Summary
Metamark Genetics Inc. (molecular diagnostics for cancer) raised $22mm from three investors in its Series B round. According to a Form D, the company plans to bring in a total of $42mm, with $8mm of that committed by the lead investor and payable upon achievement of certain milestones.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Metamark Genetics brings in $22mm through start of Series B; later adds $13mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice